Antigenix Therapeutics, Inc. — Form D
Antigenix Therapeutics, Inc. of PRINCETON, NJ, a company, filed a Form D exempt-offering notice with the SEC on 2025-10-24. The offering totals $8.4M, of which $3.4M was reported sold. Industry: Other Health Care.
Offering
- Filed: 2025-10-24
- Form: D
- Accession: 0002073993-25-000001
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $8.4M
- Amount sold: $3.4M
- Remaining: $5.0M
- Investors: 17
- Date of first sale: 2025-10-22
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-562071
Issuer
- Name: Antigenix Therapeutics, Inc.
- CIK: 0002073993
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2024
- Address: 300 CARNEGIE CENTER, SUITE 150, PRINCETON, NJ, 08540
- Phone: (317) 552-5240
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| Kwesi Frimpong-Boateng | Director | New Jersey, NJ |
| Shaun Hawkins | Director | Fishers, IN |
| Christopher Whitfield | Director | New Jersey, NJ |
| Christopher Whitfield | Executive Officer | New Jersey, NJ |
More